DANYELZA Revenue Growth
DANYELZA net product revenues reached $20.9 million in Q1 2025, an 8% increase from the first quarter of 2024, driven by strong growth outside the U.S.
Strong Financial Position
The company maintains a strong financial position with $60.3 million in cash, providing an anticipated runway into 2027.
Ex-U.S. Revenue Surge
Ex-U.S. DANYELZA net product revenues were $7.5 million, an 816% increase compared to the prior year period, driven by growth in Western Asia, Eastern Asia, and Latin America.
Radiopharmaceutical R&D Progress
The first patient was dosed in the CD38-SADA Phase I clinical trial, and Part A of the GD2-SADA Phase I clinical trial was completed, marking significant progress in the Radiopharmaceutical business unit.
NCCN Guidelines Inclusion
DANYELZA, in combination with chemotherapy, was added to NCCN guidelines for the treatment of relapsed or refractory neuroblastoma, potentially enhancing its market position.